ITF2357 (givinostat)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for ITF2357 (givinostat), covering 2007-03-01 to 2024-01-11. Get the full timeline:
Most recent: Clinical Trial Update: Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval [Phase 1]